Oncolytics kicks off reovirus trial

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 3
Volume 18
Issue 3

Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.

Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.

Articles in this issue
Genetics opens new window on acute myeloid leukemia
Pralatrexate: Upfront Rx strategy for T-cell lymphoma
Who's News
Functional MRI boosts early staging of cervical cancer
Unseen bone lesions flare up on post-Rx NSCLC scans
Exercise jumpstarts quality of life in lung ca
Champions strikes deal with Concordia
Oncolytics kicks off reovirus trial
PET/CT picks up additional lesions not found on chest CT
Targeted therapies address hard-to-treat liver tumors
Should ADT be part of care for all patients with intermediate-risk prostate cancer?
ASTRO hosts IT project; ASCO weighs in on stimulus plan
Calculate, negotiate: Pay heed to your non-CMS fees
Breast tissue evaluation with fine-needle aspiration fast tracks cancer Rx planning
Investing in future generationsSharon Murphy, MD, views pediatric oncology as a chance to affect an entire lifetime.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.